NLRP3 and metabolic dysfunction-associated steatohepatitis: Previous studies by our group and others have reported a crucial role of NLRP3 inflammasome activation and its release during the development and progression of chronic diseases in non-cardiovascular settings such as non-alcoholic steatohepatitis (NASH)17 and kidney injury2.